MYCN and neuroblastoma: The clinical neuroblastoma risk stratification systems used by most national and international consortia (Society For Pediatric Oncology and Hematology-GPOH, International Society of Paediatric Oncology Europe Neuroblastoma Group–SIOPEN, Children’s Oncology Group-COG), as well as the International Neuroblastoma Risk Group (INRG) staging system, categorizes neuroblastomas mainly based on INSS stage, age, and MYCN status into low risk, intermediate risk, and high risk19.